Published :
Tables : 63
Figures : 41
Category : Healthcare
No. of Pages : 210
Report Code : HC-1289
Genomics Market is estimated to value over USD 41 billion by 2027 end with a CAGR of over 12.6% during the forecast period 2020 to 2027. The augmentation of the genomic pool data owing to research and development activities has allowed biologists, patients and physicians to further understand the predisposition of genomes to specific diseases. Applications of this pool of data is predicted to be an integral factor in the transformation of the healthcare system with reference to more effective, reliable and accurate solutions for managing diseases. The research and healthcare community are making efforts to effectively integrate genetic information into clinical systems. Multiple clinical centres, for instance, Stanford Health Care, have taken initiatives in using the accessible information of genes in order to design a regime of personalized treatment. This aids in bridging the gap between clinical treatment and diagnosis and translational research. Rising number of investments done by the biotechnology companies, the funding agencies and the government to speed up the research activities in genomics is predicted to have major consequences on the global genomics market growth. International bodies like Welcome Trust and NIH are providing financial backing for genetic studies, which is expected to spur the genomic research scenario in developing as well as developed economies. The most crucial factor predicted to affect the proliferation of this market is to what extent the healthcare community will use the accessible information of genomes for personalized medicine. Scientists are combining diagnostics with the data generated from sequencing, which is an effective technique in inflating the landscape of personalized treatment. Generating a lot of data for genomic sequencing has resulted into substantial augmentation of functional genomics. The development of technologies providing high-throughput for protein as well as gene research studies has bolstered the segment growth. The genome industry is making progress from analysing proteomes and the entire genome sequence as well as individual genes within a short span of time shows the proliferation of this segment. Integration of solutions providing high-throughput in genomics that are functioning has offered the likeability of productive drugs with lesser harmful effects. Moreover, the usage of behavioural genetics hold immense global market potential for evaluating peculiarities of particular behaviour and competitive hypotheses with respect to modules. With the decline in the cost of gene sequencing and improvement in the provision of genetic and informatics solutions are now comprehensively available in different sectors ranging from clinical settings to small labs. Important user segments include biotechnology and pharmaceutical companies, academic and government institutes, clinics and hospitals and other end users. Amidst all these segments, the biotechnology and pharmaceutical companies accounted the largest global genomics market share due to an increase in genetic research activities that focused at development of effective drugs with fewer side effects and improving the process of drug discovery. The Asia Pacific region is predicted to exhibit rapid growth in the upcoming years. The infrastructural development in these nations has resulted into the risen insistence for biomarkers to be used for diagnosis. The global market is projected to proliferate due to an increase in the awareness and adoption of numerous genomic technologies in the developing nations such as India and China for prognosis, detection and treatment of multiple genetic disorders for instance, cancer, diabetes and others. Key market players include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Merck KGaA, Danaher Corporation, Waters Corporation, Bio-Rad Laboratories, Inc., Bruker Corporation, GE Healthcare, Perkinelmer, Inc., Luminex Corporation, Creative Proteomics, Promega Corporation. Genomics Market Segmentation: By Product and Service Consumables Systems & Software Services By Technology PCR Sequencing Microarray Nuclei Acid Extraction and Purification Other Technologies By Application Diagnostics Drug Discovery Precision Medicine Agriculture & Animal Research Other Applications By End User Research Centres and Academic & Government Institutes Hospitals & Clinics Pharmaceutical & Biotechnology Companies Other End Users By Region North America Europe Asia Pacific Latin America Middle East & Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global genomics market by product and service, by technology, by application, by end user and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencie Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The augmentation of the genomic pool data owing to research and development activities has allowed biologists, patients and physicians to further understand the predisposition of genomes to specific diseases. Applications of this pool of data is predicted to be an integral factor in the transformation of the healthcare system with reference to more effective, reliable and accurate solutions for managing diseases.
The research and healthcare community are making efforts to effectively integrate genetic information into clinical systems. Multiple clinical centres, for instance, Stanford Health Care, have taken initiatives in using the accessible information of genes in order to design a regime of personalized treatment. This aids in bridging the gap between clinical treatment and diagnosis and translational research.
Rising number of investments done by the biotechnology companies, the funding agencies and the government to speed up the research activities in genomics is predicted to have major consequences on the global genomics market growth. International bodies like Welcome Trust and NIH are providing financial backing for genetic studies, which is expected to spur the genomic research scenario in developing as well as developed economies.
The most crucial factor predicted to affect the proliferation of this market is to what extent the healthcare community will use the accessible information of genomes for personalized medicine. Scientists are combining diagnostics with the data generated from sequencing, which is an effective technique in inflating the landscape of personalized treatment.
Generating a lot of data for genomic sequencing has resulted into substantial augmentation of functional genomics. The development of technologies providing high-throughput for protein as well as gene research studies has bolstered the segment growth. The genome industry is making progress from analysing proteomes and the entire genome sequence as well as individual genes within a short span of time shows the proliferation of this segment. Integration of solutions providing high-throughput in genomics that are functioning has offered the likeability of productive drugs with lesser harmful effects. Moreover, the usage of behavioural genetics hold immense global market potential for evaluating peculiarities of particular behaviour and competitive hypotheses with respect to modules.
With the decline in the cost of gene sequencing and improvement in the provision of genetic and informatics solutions are now comprehensively available in different sectors ranging from clinical settings to small labs. Important user segments include biotechnology and pharmaceutical companies, academic and government institutes, clinics and hospitals and other end users. Amidst all these segments, the biotechnology and pharmaceutical companies accounted the largest global genomics market share due to an increase in genetic research activities that focused at development of effective drugs with fewer side effects and improving the process of drug discovery.
The Asia Pacific region is predicted to exhibit rapid growth in the upcoming years. The infrastructural development in these nations has resulted into the risen insistence for biomarkers to be used for diagnosis. The global market is projected to proliferate due to an increase in the awareness and adoption of numerous genomic technologies in the developing nations such as India and China for prognosis, detection and treatment of multiple genetic disorders for instance, cancer, diabetes and others.
Key market players include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Merck KGaA, Danaher Corporation, Waters Corporation, Bio-Rad Laboratories, Inc., Bruker Corporation, GE Healthcare, Perkinelmer, Inc., Luminex Corporation, Creative Proteomics, Promega Corporation.
Genomics Market Segmentation:
By Product and Service
By Technology
By Application
By End User
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Genomics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Genomics Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Genomics Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Genomics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Genomics Market, By Product and Service Historical Analysis and Forecast 2020-2027 (USD Million) 7.1 Consumables 7.2 Systems & Software 7.3 Services 8. Global Genomics Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. PCR 8.2. Sequencing 8.3. Microarray 8.4. Nuclei Acid Extraction and Purification 8.5. Other Technologies 9. Global Genomics Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Diagnostics 9.2. Drug Discovery 9.3. Precision Medicine 9.4. Agriculture & Animal Research 9.5. Other Applications 10. Global Genomics Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Research Centres and Academic & Government Institutes 10.2. Hospitals & Clinics 10.3. Pharmaceutical & Biotechnology Companies 10.4. Other End Users 11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 16.1 Thermo Fisher Scientific, Inc. 16.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2 Agilent Technologies, Inc 16.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3 Merck KGaA 16.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4 Danaher Corporation 16.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5 Waters Corporation 16.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6 Bio-Rad Laboratories, Inc. 16.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7 Bruker Corporation 16.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8 Bio-Rad Laboratories 16.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9 GE Healthcare 16.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10 Perkinelmer Inc. 16.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11 Luminex Corporation 16.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12 Creative Proteomics 16.12.1. Company Overview (HQ, Business Segments, Employee Strength) 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13 Promega Corporation. 16.13.1. Company Overview (HQ, Business Segments, Employee Strength) 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics